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Six lysyl residues of human thrombin (LyW, LysBs2, Ly+, Lysai 06, Lys*l” and LysBis”) have been previously shown to participate in the binding 
site of hirudin, a thrombin-specitic nhibitor [(1989) J. Biol. Chem. 264,7141-71461. In this report, we attempted to delineate the region of hirudin 
which binds to these basic amino acids of thrombin. Using the N-terminal core domains (r-Hirr-43 and r-Hirr-s2) derived from recombinant hirudins 
and synthetic C-terminal peptides (HiFs and Hir 5E65) - all fragments form complexes with thrombin - we are able to demonstrate that the 
structural elements of hirudin which account for the shielding of these 6 lysyl residues are exclusively located within the acidic C-terminal region. 
Since hirudin C-terminal peptides were shown to bind to a non-catalytic site of thrombin and inhibit its interaction with fibrinogen [(1987) FEBS 
Lett. 211, i&16], our data consequently imply that these 6 lysyl residues are constituents of the fibrinogen recognition site of thrombin. 
Hirudin; Hirudin C-terminal peptide; Hirudin C-terminal peptide/thrombin i teraction 
1. INTRODUCTION 
Hirudin is a potent thrombin inhibitor isolated from 
the bloodsucking leech Hirudo medicinalis [1,2]. It 
binds to a-thrombin with exceedingly high affinity [3] 
and specificity [4] and blocks the clotting activity of the 
protease. Hirudin is a 65-amino-acid pol~eptide [S] 
which contains 3 disulfide linkages at the N-terminal 
region [6] and a cluster of acidic residues at the C- 
terminal region. While the N-terminal domain is highly 
resistant to enzymatic digestion, the acidic C-terminal 
segment of hirudin (approximately 14 residues) is freely 
accessible to endo- and exo-peptidases and its intact- 
ness is essential to the activity of the inhibitor 171. The 
C-terminal sequence of hirudin also exhibits an intrigu- 
ing structural homology to both fibrinopeptides A and 
B. These observations lead to the following hypothesis 
[7]: (i) hirudin is a tadpole-like molecule with a com- 
pact N-terminal head and a hy~oph~ic C-terminal tail; 
and (ii) the acidic C-terminal tail of hirudin binds 
specifically to a site on thrombin which is required for 
fibrinogen recognition [8,9l and that this binding 
together with the reactive site (hirudin)-active site 
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(thrombin) interaction account for the tight and 
specific complex formation of hirudin and thrombin. 
Several ines of evidence subsequently confirmed this 
proposed model. (i) Synthetic C-terminal peptides of 
hirudin containing the last lo-20 amino acid residues 
were shown to bind thrombin and impair the clotting 
activity of the protease [lo-121. However, these pep- 
tides did not affect the catalytic site of the enzyme. (ii) 
Site-directed mutagenesis demonstrated that replace- 
ment of acidic amino acids at the C-terminal region of 
hirudin drastically reduced the binding affinity of the 
inhibitor [13]. (iii) NMR studies revealed hirudin as a 
tadpole-shape molecule having its C-terminal tail 
floating without defined conformation (14,151. Despite 
those progresses, the site of thrombin to which the 
hirudin C-terminal peptides bind remains to be unravel- 
ed. Recently, we have shown that 6 lysyl residues of 
thrombin were protected upon binding of thrombin 
[ 161. The corresponding structural components of 
hirudin which shield these 6 lysines also remain to be 
elucidated. This study was therefore undertaken to pro- 
vide answers to these two relevant questions. 
2. EXPERIME~AL 
2.1. Materials 
Human cr-thrombin was purchased from the Center for Diagnostic 
Products (Boston, USA). Recombinant desulfato hirudin 
(CGP-39393) has been produced by Ciba-Geigy in collaboration with 
Plantorgan KG (D-2903 Bad Zwis~he~n, FRG) [17]. Hirudin C- 
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terminal peptides (Hir40F6s and Hir52-65) were synthesized by solid- 
phase technique using Fmoc strategy starting from a dimethoxy- 
benzhydryl-protected C-terminal Gin at the alkoxy-benzylalcohol 
resin. Coupling protocols were as described [18]. Structures of the 
HPLC-purified peptides were confirmed by FAB-MS. The N- 
terminal core domain r-Hir’-43 was prepared from limited proteolysis 
of recombinant hirudin by VS protease, followed by purification with 
HPLC [19]. The core domain r-Hir*-sz was prepared as described in 
[20]. Purities of r-Hir’-43, r-Hir’-“, Hir40-65 and Hir52-6s were 
ascertained by quantitative N-terminal analysis [21] and amino acid 
analysis [22]. The anti-hiru~n monoclonal antibody (MAb 
4049-83-12) was prepared as described [23]. S-DABITC was syn- 
thesized ’ laboratory v41. Trypsin 
(L-l-tosylamidbn-2-phe$thyl chloromethyl ketone-treated) was ob- 
tained from Cooper Biochemical. 
2.2. S-DABITC modification of thrombin and hirudin-thrombin 
complex 
Thrombin (0.5 mg) was first incubated with intact r~ombin~t 
hirudin (125 fig), r-Hir’-43 (200 pg), r-Hirie5’ (250 pg). Hir““-65 
(0.5 mg) or Hir s2-65 (0.5 mg and 25 pg) in 250 ~1 of 50 mM sodium 
bicarbonate (PH 8.3) for 5 min. A control sample containing 0.5 mg 
of thrombin alone was carried out in parallel. Derivatization with S- 
DABITC was performed as described in [16]. 
2.3. Structural a~aiys~ of S-DA~rT~-modified proteins 
Modified thrombin and h~~~n/thrombin complexes were first 
reduced with dithiothreitol in 0.5 M Tris-HCl buffer (pH 8.4, con- 
taining 5 M guanidine chloride) and then treated with iodoacetic 
acid. Thrornbin B-chain (259 a.a), hirudin (65 a.a), r-Hir’-43, r- 
Hir’-“, thrombin A-chain (36 a.a.) and Hir52-65 were separated by 
the chromatographic system described in [16]. The fractions contain- 
ing thrombin B-chain (I) and A-chain (III) were freeze-dried and 
digested with trypsin (1:20 by weight to the substrate) in 100~1 of 
50 mM ammonium bicarbonate solution for 4 h. The digested 
samples were directly injected onto HPLC for analysis (fig.1). Purity 
and structure of S-DABITC-labeled peptides were analyzed by quan- 
titative N-terminal analysis [21] and automatic sequencing [25]. 
3. RESULTS AND DISCUSSION 
3.1. The compact N-terminal domain of hirudin blocks 
the catalytic site of thrombin 
Both r-Hir*-43 [19] and r-Hi?-” [20] form com- 
plexes with cY-thrombin (with binding constants of 
300 nM and 30 nM, respectively) and block the 
amidolytic activity of the enzyme, clearly indicating 
that their binding at least involves the shielding of the 
active site of thrombin. In addition, it is very likely that 
the affinity of the hirudin N-terminal core domain to 
thrombin is also enhanced by hydrophobic interaction 
involving an apolar binding pocket adjacent to the ac- 
tive site of the protease (fig.2) [19,26-281. There is 
good evidence which suggests that r-Hirle5* retains 
essentially the same conformation as the corresponding 
segment of the intact hirudin. A monoclonal antibody 
(MAb 4049-83-12) raised against intact recombinant 
hirudin recognized a conformation-dependent epitope 
encompassing G1u43 and Lys4’ [23]. This antibody ex- 
hibited 90% cross-reactivity toward both intact hirudin 
and r-Hirim5*. In addition, the antibody completely 
neutralized the anticoagulant activity of r-Hir’-” (data 
not shown). r-Hi?-‘* as well as r-Hir’-43 (data not 
shown), however, both failed to protect most of the 
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lysyl residues which were shown to be shielded by the 
intact hirudin (fig.lA-C) [16]. In the free thrombin 
(fig. 1 A), approximately 9 lysyl residues of the B-chain 
were preferenti~ly modified by S-DABITC. These lysyl 
residues included LysB65 (fraction l), LysB77 (fraction 
2), LysB21 (fraction 3), LysB176 (fraction 4), LysB154 and 
LysB5* (fraction 5), LysBlo6 and LysB1*’ (fraction 6). 
Upon binding of 1.2 molar of intact hirudin (fig.lB), 
the modification of 7 lysyl residues (LysB2r, LysB5*, 
LysBCf, LYS’~~, LysB1%, LysB”’ and LysBlf4) was 
6 
THROMBIN 
THROMBIN + 4 
HIRUDIN 
I 
THRoMBIN + 
z HIR 
l-52 
2 
THR~MBIN + 
,,rR52-65 
4 
Fig. 1. Tryptic peptide maps of S-DABITC-labeled thrombin B-chain. 
Samples were derived from modified free thrombin (A), 
hirudin-thrombin complex (B), r-Hir’-52-thrombin complex (C), 
and Hirs2-65-thrombin complex (D). Conditions of tryptic digestion 
are described in the text. 10 pl containing 3 yg of the digested sample 
were injected. Chromatographic conditions are as follows. The 
column was Vydac C-18, 5/tm; temperature 22°C; solvent A was 
17.5 mM sodium acetate, pH 5.0; solvent B was acetonitrile; gradient 
was 20-50% B (finear) in 40 min. Detector, 436 nm, 0.02 absorbance 
units at full scale. 
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Fig.2. Diagram illustrating the corresponding binding sites of r- 
Hir1-s2 and Hir52-6s to human a-thrombin. The N-terminal compact 
domain (r-Hir’-52) binds to the catalytic site (C) and apolar binding 
site (AB). The C-terminal domain (Hir s2-65) binds to the recognition 
site (R). Seven lysyl residues of the thrombin B-chain were identified 
to be located within the recognition site. They are LysB2’, LysB5*, 
Lyst=, LysB”, LysB’o6, LysB’O’ and LysBts4. Negative charges in the 
Hi?@ (recombin~t hirudin is devoid of a sulfate group at Tyr63), 
3 disulfide linkages (e) and 3 lysine residues (B) in r-Hir’-” are 
also indicated. 
drastically reduced [ 161. The extent of shielding ranged 
from 70070 to greater than 97%. Binding of r-Hirle5’, 
on the other hand, yielded a pattern of labeling very 
similar to that of free thrombin (fig.lC). The only 
noticeable difference was observed with fraction 5. 
This fraction contained multiple peptides which were 
difficult to separate. Sequence analysis of fraction 5 
derived from free thrombin (fig.lA) revealed two ma- 
jor color peptides which corresponded to specific S- 
DABITC modification at L~s~‘$~ and LysB5’ (table 1). 
Analysis of fraction 5 derived from the f- 
Hir’-52-thrombin complex (fig. 1C) gave only one ma- 
Table 1 
Amino acid sequences of S-DABITC-labeled peptides 
Fraction 
number 
Amino acid sequences 
1 I-G-K*-H-S-R (63-68) 
2 N-I-E-K*-I-S-M-L-E-K (74-83) 
3 K*-S-P-Q-E-L-L-C-G-A-S-L-I-S-D-R (21-36) 
4 G-Q-P-S-V-L-Q-V-V-N-L-P-I-V-E-R-P-V-C-K*-D-S-T-R 
(155-178) 
5 (fig.lA) E-T-W-T-A-N-V-G-K*-G-Q-P-S-V-L-Q-V-V-N-L 
(146-165) 
W-V-L-T-A-A-H-C-L-L-Y-P-P-W-D-K*-N-F-T-E 
(37-56) 
5 (fig.lC) E-T-W-T-A-N-V-G-K*-G-Q-P-S-V-L-Q-V-V-N-L 
(146-165) 
6 L-K*-K*-P-V-A-F-S-D-Y-I-H-P-V-C-L-P-D-R (105-123) 
Fractions correspond to those numbered in fig. 1. S-DABITC-labeled 
lysines are denoted with (*). Numbers in parentheses indicate 
sequence positions in the B-chain of human thrombin 
jor color peptide with S-DABITC modification at 
LysB’54. Thus r-Hir’-St binding protected only LysBS2 
from S-DABITC modification. Since LysBS2 was also 
partially protected by Hir5’-@, it appears that the bin- 
ding site of r-Hir’-” and Hir52-65 may overlap at 
LyP. With the thrombin A-chain, only the cu-amino 
group of the N-terminal Thr was labeled with S- 
DABITC, and its labeling pattern was not affected by 
binding of either intact hirudin or t-Hir’-52. In free 
thrombin, hirudin-thrombin complex and r- 
Hir~-52-thrombin complex, the extent of modification 
at the N-terminal Thr of the thrombin A-chain was 
89%, 90% and 8490, respectively. 
3.2. The acidic C-terminal segment of hirudin 
(Hir4’- 6s and Hi?“‘) binds to a protein 
recognition site of thrombin which is independent 
of the catalytic site and is comprised of basic 
amino acid residues 
Synthetic C-terminal peptides of hirudin with sizes 
ranging from 10 to 21 residues have been shown to bind 
thrombin, inhibit the thrombin-mediated release of 
fibrinopeptides and fibrin clot formation [IO], as well 
as increase the activated partial thromboplastin time 
[12]. However, none of these peptides displayed the 
ability to inhibit the thrombin activity to hydrolyze the 
tripeptide substrate. These results strongly suggest hat 
hirudin C-terminal peptides bind to a non-catalytic site 
of thrombin which is required for thrombin-fibrinogen 
interaction (recognition). The elucidation of the bin- 
ding site of hirudin C-terminal peptides on thrombin is 
therefore of critical importance to our understanding 
of the mechanism of thrombin specificity at the 
molecular level. We have shown in fig.lB that intact 
hirudin protects LysB2i, LysBJ2, LysB6*, L~s~‘~, 
LysBro6, LysB1*’ and LysBls4 of the B-chain from 
chemical modification. In the experiments with hirudin 
C-terminal peptides, we were able to demonstrate that 
binding of Hir40-65 and Hir52-65 could as well shield all 
these lysyl residues (fig.lD). The extent of shielding 
was dependent upon the molar ratio of 
Hir52-65/thrombin. At a molar ratio of 20 (fig. lD), the 
percentages of shielding were 96% (LysB6’), 70% 
(LysB”), 91% fLysB2’), 80% (L~s~‘~~) and 94% 
(LysBlo6 and LysB’*’ ), respectively. At an equal molar 
ratio, the protections were,62~0, 4OV0, 55%, 42% and 
56%) respectively. Based on the protein concentrations 
used for S-DABITC labeling, the binding affinity of 
Hir32-65 was calculated to be 1.3 x 10e5 M, a figure 
which is consistent with that reported by Krstenansky 
and Mao [lo]. 
Some of the lysyl residues shielded by Hir52-65 have 
long been suspected to be located at the fibrinogen 
recognition site of cu-thrombin. LysB6’ and L~s~‘~ are 
very close to an autolytic site which converts CY- to ,& 
thrombin 129-311, and LysBlf4 is located precisely at 
the autolytic site which converts CY- to ~-thrombin 
289 
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[29,31]. Both ,& and y-thrombins lack clotting activity, 
but retain essentially intact catalytic activity and 
specificity against many non-fibrinogen substrates [3 11. 
Antibodies raised against peptides containing residues 
62-73 of thrombin B-chain competitively inhibit the 
binding of hirudin to cY-thrombin [32]. Thus it is clear 
that either shielding or breakdown of this recognition 
site produces a defective form of thrombin devoid of 
ability to release the fibrinopeptides from ~brinogen. 
In addition to lysyl residues, the arginyl residues are 
most likely also part of the recognition site. If we 
assume that the recognition site of rr-thrombin consists 
of all the lysyl residues shielded by Hirs2-65, plus the 3 
arginines located in between LysB65 and LysB7’ (ArgB6*, 
ArgB7’ and ArgB73), then there will be at least 10 
Lys/Arg residues participating in this unique site. 
Our data unequivocally demonstrate that the struc- 
tural elements of hirudin which bind to the fibrinogen 
recognition site of thrombin are exclusively located 
within the C-terminal segment of the inhibitor. These 
results and available data [19,20] further confirm the 
proposal [7] that the N-terminal core domain and the 
C-terminal tail of hirudin bind to independent sites of 
thrombin (fig.2) and that the exceedingly high binding 
affinity of the hirudin-thrombin complex is a conse- 
quence of cooperative multiple bindings [31]. One in- 
volves the classical reactive/active site interaction in 
which specificity and affinity are enhanced by a 
hydrophobic binding pocket adjacent to the active site 
of thrombin [26-28,331. The other is the specific in- 
teraction between the acidic C-terminal tail of hirudin 
and the basic recognition site of thrombin, as 
elucidated in this report. 
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